Nova-Pheno
Categorie
Nova-Pheno Les marques, Nova-Pheno Analogs
- Adonal
- Aephenal
- Agrypnal
- Amylofene
- Aphenylbarbit
- Aphenyletten
- Barbenyl
- Barbinal
- Barbiphen
- Barbiphenyl
- Barbipil
- Barbita
- Barbivis
- Barbonal
- Barbophen
- Bardorm
- Bartol
- Bialminal
- Blu-Phen
- Cabronal
- Calmetten
- Calminal
- Cardenal
- Chinoin
- Codibarbita
- Coronaletta
- Cratecil
- Damoral
- Dezibarbitur
- Dormina
- Dormiral
- Dormital
- Doscalun
- Duneryl
- Ensobarb
- Ensodorm
- Epanal
- Epidorm
- Epilol
- Episedal
- Epsylone
- Eskabarb
- Etilfen
- Euneryl
- Fenbital
- Fenemal
- Fenobarbital
- Fenosed
- Fenylettae
- Gardenal
- Gardepanyl
- Glysoletten
- Haplopan
- Haplos
- Helional
- Hennoletten
- Henotal
- Hypnaletten
- Hypnette
- Hypno-Tablinetten
- Hypnogen
- Hypnolone
- Hypnoltol
- Hysteps
- Lefebar
- Leonal
- Lephebar
- Lepinal
- Lepinaletten
- Linasen
- Liquital
- Lixophen
- Lubergal
- Lubrokal
- Lumen
- Lumesettes
- Lumesyn
- Luminal
- Lumofridetten
- Luphenil
- Luramin
- Molinal
- Neurobarb
- Nirvonal
- Noptil
- Nova-Pheno
- Nunol
- Parkotal
- Pharmetten
- Phen-Bar
- Phenaemal
- Phenemal
- Phenemalum
- Phenobal
- Phenobarbital
- Phenobarbitol
- Phenobarbituric Acid
- Phenobarbyl
- Phenoluric
- Phenolurio
- Phenomet
- Phenonyl
- Phenoturic
- Phenylethylbarbiturate
- Phenylethylbarbituric Acid
- Phenylethylmalonylurea
- Phenyletten
- Phenyral
- Phob
- Polcominal
- Promptonal
- Seda-Tablinen
- Sedabar
- Sedicat
- Sedizorin
- Sedlyn
- Sedofen
- Sedonal
- Sedonettes
- Sevenal
- Sinoratox
- SK-Phenobarbital
- Solfoton
- Solfoton Talpheno
- Solu-Barb
- Sombutol
- Somnolens
- Somnoletten
- Somnosan
- Somonal
- Spasepilin
- Starifen
- Starilettae
- Stental
- Stental Extentabs
- Talpheno
- Teolaxin
- Teoloxin
- Thenobarbital
- Theoloxin
- Triabarb
- Tridezibarbitur
- Triphenatol
- Versomnal
- Zadoletten
- Zadonal
Nova-Pheno Les marques melange
Nova-Pheno Formule chimique
C12H12N2O3
Nova-Pheno RX lien
No information avaliable
Nova-Pheno FDA fiche
Nova-Pheno msds (fiche de securite des materiaux)
Nova-Pheno Synthese de reference
Hoerlein, le brevet américain. 1,025,872 (1912)
Nova-Pheno Poids moleculaire
232.235 g/mol
Nova-Pheno Point de fusion
174 oC
Nova-Pheno H2O Solubilite
Nova-Pheno Etat
Solid
Nova-Pheno LogP
1.777
Nova-Pheno Formes pharmaceutiques
Tablet; Elixir
Nova-Pheno Indication
Pour le traitement de l'épilepsie
Nova-Pheno Pharmacologie
Le phénobarbital, la plus longue durée d'action barbituriques, est utilisé pour ses propriétés anticonvulsivantes et sédatifs-hypnotiques dans la gestion de tous les troubles épileptiques, sauf absence (petit mal).
Nova-Pheno Absorption
Absorbé à des degrés divers après une administration orale, rectale ou parentérale. Les sels sont plus rapidement absorbés que sont les acides. Le taux d'absorption est augmentée si le sel de sodium est ingérée comme une solution diluée ou pris sur un estomac vide
Nova-Pheno Toxicite
SNC et de dépression respiratoire qui peut évoluer vers la respiration de Cheyne-Stokes, aréflexie, constriction des pupilles à un degré léger (bien que dans une grave intoxication ils peuvent wshow la dilatation paralytique), oligurie, tachycardie, hypotension, a abaissé la température du corps, et le coma. Le syndrome de choc typique (apnée, collapsus circulatoire, l'arrêt respiratoire et la mort) peuvent survenir.
Nova-Pheno Information pour les patients
PATIENT INFORMATION
Practitioners should give the following information and instructions to patients receiving barbiturates:
1. The use of phenobarbital carries with it an associated risk of psychological and/or physical dependence.
The patient should be warned against increasing the dose of the drug without consulting a physician.
2. Phenobarbital may impair mental and/or physical abilities required for the performance of potentially
hazardous tasks (e.g., driving, operating machinery, etc.).
3. Alcohol should not be consumed while taking phenobarbital. Concurrent use of phenobarbital with other
CNS depressants (e.g., alcohol, narcotics, tranquilizers, and antihistamines) may result in additional CNS
depressant
Practitioners should give the following information and instructions to patients receiving barbiturates:
1. The use of phenobarbital carries with it an associated risk of psychological and/or physical dependence.
The patient should be warned against increasing the dose of the drug without consulting a physician.
2. Phenobarbital may impair mental and/or physical abilities required for the performance of potentially
hazardous tasks (e.g., driving, operating machinery, etc.).
3. Alcohol should not be consumed while taking phenobarbital. Concurrent use of phenobarbital with other
CNS depressants (e.g., alcohol, narcotics, tranquilizers, and antihistamines) may result in additional CNS
depressant
Nova-Pheno Organismes affectes
Les humains et autres mammifères
